Therapeutic strategies that target tau pathology may be more clinically effective than Aβ-directed therapies (Giacobini and Gold, 2013), and very recent studies have suggested that misfolded hyperphosphorylated tau proteins play an important role in AD synaptic dysfunction (Tai et al., 2012; Sokolow et al., 2014). The gene discussed is MAPT; the disease is Alzheimer disease.